echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Novartis announces overall survival data for MET inhibitors

    Novartis announces overall survival data for MET inhibitors

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, at the American Society of Clinical Oncology in 2021, Novartis announced the latest phase 2 clinical trial data of the oral highly selective small molecule MET inhibitor Tabrecta in the treatment of adult patients with metastatic non-small cell lung cancer
    .


    These patients carry genetic mutations that cause the skipping of exon 14 of the MET gene


    Recently, at the American Society of Clinical Oncology in 2021, Novartis announced the latest phase 2 clinical trial data of the oral highly selective small molecule MET inhibitor Tabrecta in the treatment of adult patients with metastatic non-small cell lung cancer
    .


    These patients carry genetic mutations that cause the skipping of exon 14 of the MET gene


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.